Position of the Transparency Council – Enhertu (trastuzumab deruxtecan)
At its meeting on 23 June 2025, the Transparency Council adopted position No. 76/2025 on the appraisal of the drug Enhertu (trastuzumab deruxtecan) under the drug program “Treatment of patients with cancer of the esophagus, gastroesophageal junction, and stomach (ICD-10: C15-C16)”